CASP9 and neoplasm: In vitro:Decreasing the cell viability from 8.35 to 98.16% in a dose-dependent manner (at various concentrations: 10–25 μM)Inducing the apoptotic cell death from 23.81 to 74.59% in a dose-dependent manner (at 10–20 μM)In vivo: A two-fold decreasing the volumes of tumors at 50 mg/kgReducing tumor weight at 25 and 50 mg/kg (on day 21) and higher dose showed more significant inhibitionDecreasing the protein levels of c-FLIP, MCL-1, and XIAP (anti-apoptosis markers)Increasing the apoptosis-associated protein expressions (caspase-3, caspase-8, and caspase-9)